Your browser doesn't support javascript.
loading
Glucagon-like peptide 1 (GLP-1).
Müller, T D; Finan, B; Bloom, S R; D'Alessio, D; Drucker, D J; Flatt, P R; Fritsche, A; Gribble, F; Grill, H J; Habener, J F; Holst, J J; Langhans, W; Meier, J J; Nauck, M A; Perez-Tilve, D; Pocai, A; Reimann, F; Sandoval, D A; Schwartz, T W; Seeley, R J; Stemmer, K; Tang-Christensen, M; Woods, S C; DiMarchi, R D; Tschöp, M H.
Afiliación
  • Müller TD; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Department of Pharmacology and Experimental Therapy, Institute of Exp
  • Finan B; Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
  • Bloom SR; Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
  • D'Alessio D; Division of Endocrinology, Duke University Medical Center, Durham, NC, USA.
  • Drucker DJ; The Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Ontario, M5G1X5, Canada.
  • Flatt PR; SAAD Centre for Pharmacy & Diabetes, Ulster University, Coleraine, Northern Ireland, UK.
  • Fritsche A; German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, Departm
  • Gribble F; Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK.
  • Grill HJ; Institute of Diabetes, Obesity and Metabolism, Department of Psychology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Habener JF; Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
  • Holst JJ; Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Langhans W; Physiology and Behavior Laboratory, ETH Zurich, Schwerzenbach, Switzerland.
  • Meier JJ; Diabetes Division, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Nauck MA; Diabetes Center Bochum-Hattingen, St Josef Hospital (Ruhr-Universität Bochum), Bochum, Germany.
  • Perez-Tilve D; Department of Internal Medicine, University of Cincinnati-College of Medicine, Cincinnati, OH, USA.
  • Pocai A; Cardiovascular & ImmunoMetabolism, Janssen Research & Development, Welsh and McKean Roads, Spring House, PA, 19477, USA.
  • Reimann F; Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council, Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK.
  • Sandoval DA; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Schwartz TW; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DL-2200, Copenhagen, Denmark; Department of Biomedical Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark.
  • Seeley RJ; Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Stemmer K; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Tang-Christensen M; Obesity Research, Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
  • Woods SC; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA.
  • DiMarchi RD; Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA; Department of Chemistry, Indiana University, Bloomington, IN, USA.
  • Tschöp MH; German Center for Diabetes Research (DZD), Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany; Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
Mol Metab ; 30: 72-130, 2019 12.
Article en En | MEDLINE | ID: mdl-31767182
ABSTRACT

BACKGROUND:

The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent ß-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. SCOPE OF REVIEW In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. MAJOR

CONCLUSIONS:

Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptido 1 Similar al Glucagón Límite: Humans Idioma: En Revista: Mol Metab Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptido 1 Similar al Glucagón Límite: Humans Idioma: En Revista: Mol Metab Año: 2019 Tipo del documento: Article